Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends in Medicare Reimbursement for the Resection of Vestibular Schwannomas: 2000 to 2021.

Journal of neurological surgery. Part B, Skull base·2026
Same author

Analysis of Fall and Jump Behaviors in Freely Moving <i>Drosophila melanogaster</i> Using 58 fps Video.

Insects·2026
Same author

A Phase 2 Feasibility Study Combining Pembrolizumab and Metformin in patients with Metastatic Head and Neck Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Predictive capacity of mismatch repair status in the use of immune checkpoint inhibitors for the treatment of aggressive pituitary tumors and pituitary carcinomas: An illustrative case report and literature review.

Surgical neurology international·2026
Same author

Gross-total resection of Koos grade IV sporadic pediatric-spectrum vestibular schwannoma: A case report and review of the literature.

Surgical neurology international·2026
Same author

Genome-Wide Variations of End Motif in Cell-Free DNA Fragments Distinguish Immunotherapy Responders from Non-Responders in Head and Neck Cancer: A Multi-Institute Prospective Study.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: Jun 23, 2025

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

15.8K

Immune Checkpoint Inhibition for High Grade Meningiomas: A Systematic Review.

Joel Kaye1, John Na1, Shravan Atluri2

  • 1Department of Neurological Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

World Neurosurgery
|June 20, 2024
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitors show promise for recurrent meningiomas. Tumors with mismatch repair deficiency or high tumor mutational burden may respond better to these therapies.

Keywords:
Grade IIGrade IIIImmune checkpointMeningiomaMismatch repair

More Related Videos

Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy
09:17

Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy

Published on: September 16, 2019

6.8K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K

Related Experiment Videos

Last Updated: Jun 23, 2025

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
12:52

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

15.8K
Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy
09:17

Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy

Published on: September 16, 2019

6.8K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K

Area of Science:

  • Neuro-oncology
  • Immunotherapy
  • Genomics

Background:

  • World Health Organization grade II/III meningiomas often recur after standard treatment.
  • Effective medical therapies for recurrent meningiomas are lacking.
  • Immune checkpoint inhibitors (ICIs) are being investigated for these challenging cases.

Approach:

  • Systematic literature review following PRISMA guidelines.
  • Analysis of clinical data, tumor genomics, and outcomes from studies on recurrent meningiomas treated with ICIs.
  • Inclusion of four studies with 59 patients.

Key Points:

  • Nivolumab and pembrolizumab were the most common ICIs used.
  • Favorable responses were associated with mismatch repair deficiency and high tumor mutational burden.
  • Common adverse effects included elevated liver/pancreas enzymes, fatigue, and leukopenia/infection.

Conclusions:

  • ICIs offer a promising therapeutic avenue for recurrent grade II/III meningiomas.
  • Tumor genomics, specifically mismatch repair deficiency and high tumor mutational burden, may predict ICI efficacy.
  • Future research should focus on prospective trials with standardized genomic and response assessments.